0000950170-24-017894.txt : 20240221 0000950170-24-017894.hdr.sgml : 20240221 20240221160430 ACCESSION NUMBER: 0000950170-24-017894 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HOMCY CHARLES J CENTRAL INDEX KEY: 0001192591 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 24659341 MAIL ADDRESS: STREET 1: PORTOLA PHARMACEUTICALS, INC. STREET 2: 270 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3160 PORTER DR. STREET 2: SUITE 250 CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 3160 PORTER DR. STREET 2: SUITE 250 CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 ownership.xml 4 X0508 4 2024-02-16 0001743881 BridgeBio Pharma, Inc. BBIO 0001192591 HOMCY CHARLES J C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 true false false false false Common Stock 2024-02-16 4 M false 3760 A 1231594 D Common Stock 2024-02-16 4 F false 1509 37.21 D 1230085 D Restricted Stock Units 2024-02-16 4 M false 3760 0 D Common Stock 3760 0 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Includes 838 shares of the Issuer's Common Stock acquired by the Reporting Person on February 15, 2024 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. /s/ Brian C. Stephenson, Attorney-in-Fact 2024-02-21